Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9190 in healthy adults
NCT07142850Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of HRS-9190 (4 arms), sponsored by Hengrui. Primary endpoints: Adverse Events at 7 days and Plasma Histamine Levels. Started Aug 2025; status: completed.
02
Drugs
HRS-9190
Beyond the preview
Go deeper on NCT07142850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142850.